Immunogen, Inc.

NASDAQ:IMGN   3:59:57 PM EDT
5.65
-0.01 (-0.18%)
Products

Immunogen Announces FDA Breakthrough Therapy Designation For IMGN632 In Relapsed Or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

Published: 10/05/2020 11:00 GMT
ImmunoGen Inc (IMGN) - Immunogen Announces FDA Breakthrough Therapy Designation for Imgn632 in Relapsed Or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm.
Immunogen Inc - Updated Data From Imgn632 Monotherapy Bpdcn Dose Expansion Cohort Will Be Presented at Ash This December.